Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06658405 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions

Study acronym: HPV2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Oct 2031 to Dec 31, 2031v5
  2. Study title shortened, about 1 wordv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2024 to Jan 13, 2025
    • Site details revised
    v3
  4. Study title shortened, about 2 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions. The study aims to estimate the rate of HPV clearance within two years following an initial positive HPV control test in women over 45 years of age who are chronic HPV carriers and have undergone treatment for high-grade intraepithelial cervical lesions, and who receive HPV vaccination. The study includes two cohorts: 1. Eligible patients who consent to vaccination will participate in a prospective, single-center, single-arm, interventional clinical trial (Category 2). 2. Non-vaccinated patients will be included in a non-interventional observational study, with no changes to their standard care.
Trial Details
NCT Number NCT06658405
Lead Sponsor Centre Oscar Lambret
Collaborators: Canceropôle Nord Ouest
Conditions
(from sponsor)		 Cervical Lesion
Related terms Neoplasms
Enrollment 85 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov